TRU.AX TruScreen Group (ASX) jumps to A$0.017 pre-market 12 Feb 2026: check volume

A heavy volume spike pushed TRU.AX stock activity before the open on 12 Feb 2026, with 19,366,645 shares trading and the price at A$0.017, up 6.25% from the prior close. That surge sent the intraday high to A$0.025 and lifted relative volume to 32.55x the average. For pre-market traders on the ASX, this is a clear liquidity event to watch. We break down the drivers, technical setup, fundamentals, Meyka AI grade, and short-term price scenarios.

TRU.AX stock: volume spike and price action

The defining fact is the volume spike: 19,366,645 shares versus an average of 595,016. That pushed TRU.AX stock from the prior close A$0.016 to the pre-market quote A$0.017, a 6.25% one-day move. High intraday volatility is visible — day low A$0.017, day high A$0.025 — flagging short-term trading interest and potential order imbalances.

Trading setup and technicals for TRU.AX stock

Technicals show a mixed but tradable pattern. The 50-day average is A$0.01507 and the 200-day average is A$0.01742, so price sits near long-term average. Momentum measures include RSI 50.30 and ADX 44.16, signalling a strong trend. Volume indicators reinforce the move: OBV 556,945 and MFI 63.25, which point to buying pressure. Traders should note the high relative volume and tight spreads for intraday scalps and short-term breakouts.

Fundamentals and valuation for TRU.AX

TruScreen Group Limited trades on the ASX and develops cervical cancer detection devices. Market cap is approximately A$12,704,531 with 747,325,326 shares outstanding. Financials show EPS -0.01 and PE -1.70, reflecting ongoing losses. Key ratios include PB around 3.99, price-to-sales 9.13, and current ratio 5.05, indicating ample short-term liquidity but weak profitability metrics. Revenue per share is 0.00214 and net income per share is -0.00295.

Meyka grade and TRU.AX stock forecast

Meyka AI rates TRU.AX with a score out of 100: 66.49 (B) — Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly A$0.02 and yearly A$0.019, versus the current price A$0.017, implying a short-term upside. Forecasts are model-based projections and not guarantees.

Risks, catalysts and sector context for TRU.AX

Primary risks include continued negative earnings, thin free cash flow, and reliance on product adoption in overseas markets. The healthcare equipment sector shows modest recent gains but compares with larger peers trading at far higher multiples. Potential catalysts are regulatory approvals, distribution deals, or clinical data releases. No major company announcement appeared in major feeds during the spike; check the company site and exchanges for filings.

Execution ideas and liquidity notes for TRU.AX stock

Given the volume spike, short-term traders may use tight stop-losses and trade size limits. Consider entry above confirmed intraday support and scale out near A$0.025 resistance. Long investors should monitor quarterly cash flow and revenue growth, and expect high volatility. Use limit orders to manage slippage in the ASX market and note low market cap can magnify spreads.

Final Thoughts

Key takeaways: TRU.AX stock shows a clear pre-market volume spike on 12 Feb 2026, with 19,366,645 shares traded, a price of A$0.017, and intraday volatility to A$0.025. Technicals suggest a tradable short-term trend (RSI 50.30, ADX 44.16), while fundamentals show ongoing losses (EPS -0.01) and high valuation ratios for a small-cap device maker. Meyka AI’s forecast model projects monthly A$0.02 and yearly A$0.019, implying about +17.65% and +11.76% upside versus the current price A$0.017. Meyka AI rates TRU.AX at 66.49 (B) HOLD, but forecasts are model-based projections and not guarantees. For pre-market traders on the ASX, prioritise position sizing and confirm any regulatory or corporate filings before adding exposure.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.